Inovio Pharmaceuticals stock rises 1.74 percent to $1.17, outperforming competitors
Updated
Updated · MarketWatch · Apr 27
Inovio Pharmaceuticals stock rises 1.74 percent to $1.17, outperforming competitors
8 articles · Updated · MarketWatch · Apr 27
Shares gained for a second consecutive day, with trading volume reaching 2.9 million, surpassing the 50-day average of 1.7 million.
Inovio closed 60.72% below its 52-week high of $2.98 set on September 9. The NASDAQ Composite Index rose 0.20% while the Dow Jones fell 0.13%.
Compared to competitors, Johnson & Johnson fell 0.95%, Statera Biopharma surged 6,550%, and Pfizer declined 0.78%, reflecting a mixed session for pharmaceutical stocks.
After a 6,550% surge, is a competitor's strategic pivot the model Inovio should have followed?
Inovio halted its stock program. How will it fund a potential drug launch without this financing tool?
With cash reserves dwindling, can Inovio survive to see its lead drug approved by the FDA this October?
The FDA has flagged concerns; is Inovio's biggest hope for approval already in jeopardy before its deadline?
Why do analysts see a $6.75 target for a stock trading near $1? What are they seeing?